In the specialized field of biochemical research and immunological studies, the gp-33 peptide stands out as a foundational tool. As someone who has spent significant time sourcing and analyzing various reagents for laboratory applications, I have found that understanding the nuances of this specific sequence is essential for anyone involved in high-level cellular interaction studies.
Understanding the GP-33 Peptide Sequence
The GP33-41 sequence is perhaps the most well-known iteration of this molecule. It is a 9-amino acid long peptide derived from the glycoprotein of the Lymphocytic Choriomeningitis Virus (LCMV). When sourcing this material, researchers often distinguish between two primary sequence variations: KAVYNFATM and KAVYNFATC.
The KAVYNFATC is a linear peptidic epitope that serves as a critical reference point in many experimental setups. Meanwhile, KAVYNFATM is frequently cited in literature as the wild-type sequence. When I evaluate the quality of a LCMV GP (33-41) peptide, I look for these specific residues, as the precision of the sequence determines its binding affinity to H-2Db molecules.
Technical Specifications and Variants
Beyon LCMV gp33-41 | CAS NO.:151705-84-9 d the standard 9-mer, the study of the GP33-43 peptide highlights how s LCMV (33–41), GP33H-2Db restricted epitope derived from the Lymphocytic Choreomeningitis Virus (LCMV) glycoprotein gp 33; residues 33 to 41. tructural variations can impact MHC class I binding. In my own experience with these reagents, I have encountered eight reduced peptide bond Ψ(CH2–NH) analogues, which are fascinating for researchers investigating the structural basis of peptide-MHC interactions. These modifications allow for a deeper look into how subtle chemical shifts influence the stability of the peptide complex.
For those curious about the GP33 epitope, it is important to note that it is an H-2Db restricted epit Peptide Antigen Treatment of Naive and Virus-Immune Mice ope. This specificity is why it remains a gold standard in immunology. Whether you are using a GP33 tetramer to visualize antigen-specific cells or performing a kinetic analysis, the reliance on this GP33 CD8 epitope is widespread because of its predictable behavior in vitro.
Practical Observations
When discussing the LCMV (33–41), GP33, it is worth mentioning that the GP(33-41), a 9-aa-long peptide is the optimized length for these studies. I have often found that the LCMV gp33 peptide KAVYNFATM (H-2 Db) is the most consistent choice for those who need to ensure high-purity stimulation in their assays.
Regarding the GP33 and GP66 peptide combinations, I have observed tha Characterization of CD8 T Cell-Mediated Mutations in the t these are frequently used in tandem to provide a comprehensive view of T-cell responses. The ability of the peptide gp33 to interact effectively with the immune system is why it is considered an immunodominant target.
Insights for Researchers
For those looking into the LCMV gp33–41 H-2Db complex, it is crucial to handle the product according to manufacturer guidelines, typically involving storage at -20°C or -80°C to maintain structural integrity. I have found that the GP33-41 remains st A Role for the Chemokine RANTES in Regulating CD8 T able when reconstituted properly, and its capacity to can stimulate the proliferation of purified single gp33-reactive CD8 T cells makes it an invaluable asset for controlled experiments.
In summary, whether you are investigating the 33 to 41 residue range or comparing different gp33 analogues, the quality of the synthesis is paramount. Always verify the sequence (e.g., KAVYNFATM) against your specific research requirements LCMV (33–41), GP33 - 1 mg to ensure the GP33 reagent performs as expected in your LCMV gp33-41 studies. The derived from the glycoprotein (GP33 peptide) nature of this molecule continues t This is the H-2Db restricted epitope derived from the residues 33 to 41 of Lymphocytic Choreomeningitis Virus (LCMV) glycoproteingp 33. o provide deep insights into cellular recognition, making it a staple in any advanced laboratory.